Daveen Chopra - 07 May 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Surgical Structural Heart
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
07 May 2022
Net transactions value
-$1,337,419
Form type
4
Filing time
10 May 2022, 20:54:29 UTC
Previous filing
05 May 2022
Next filing
17 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability $30,659 -305 -1.6% $100.52 18,493 07 May 2022 Direct
transaction EW Common Stock Options Exercise $0 +8,531 +46% $0.000000 27,024 08 May 2022 Direct F1
transaction EW Common Stock Tax liability $449,224 -4,469 -17% $100.52 22,555 08 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $857,536 -8,531 -44% $100.52 10,968 08 May 2022 Common Stock 8,531 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.